Last updated: March 17, 2025
Sponsor: Beijing Friendship Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Vascular Diseases
Dizzy/fainting Spells
Circulation Disorders
Treatment
terlipressin
Clinical Study ID
NCT06855758
2025-P2-023-01
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with end-stage renal disease aged 18 years or above
Exclusion
Exclusion Criteria:
simultaneous multiple organ transplantation
known allergy to study medication
known pregnancy status
cancellation of surgery due to grafts or personal reasons
persistent severe preoperative hypertension that may not require intraoperativesupportive therapy with vasoactive medications
any other reason that the supervising physician or the anesthesiologist on dutythink the patient is not suitable for the study
Study Design
Total Participants: 150
Treatment Group(s): 1
Primary Treatment: terlipressin
Phase:
Study Start date:
March 06, 2025
Estimated Completion Date:
June 30, 2027
Connect with a study center
Beijing Friendship Hospital
Beijing,
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.